Dr. Sumona Das

Dr. Sumona Das – Top Medical Oncologist & Cancer Expert, Khulna

Dr. Sumona Das is a Consultant in the Medicine Unit at Khulna Medical College & Hospital, Khulna, with over 10 years of distinguished clinical, academic, and systemic oncology experience. As an eminent Medical Oncologist and Medicine Specialist, she provides expert care for severe and complex malignancies, uniquely focusing on highly aggressive genetic and hereditary cancer syndromes such as Li-Fraumeni syndrome, multiple endocrine neoplasia, Von Hippel-Lindau disease, hereditary breast cancer, and Lynch syndrome. Patients seeking expert oncological evaluation receive evidence-based treatments tailored to halt disease progression, manage acute systemic crises, and achieve long-term remission through personalized medicine. Her medical practice combines high-precision genetic profiling with individualized, systemic patient care plans.

Professional Biography

Dr. Sumona Das completed her MBBS degree, establishing a comprehensive clinical foundation in general medical sciences. Demonstrating a profound commitment to systemic disease and cancer care, she entered the prestigious BCS (Health) cadre. She pursued highly rigorous postgraduate specializations, earning her Doctor of Medicine (MD) in Medical Oncology and completing FCPS (Medicine, Part 2). This exceptional combination of internal medicine and medical oncology equips her with the advanced medical expertise required to manage highly complex malignancies and their systemic effects on the entire body. Finding the best Oncologist in Khulna leads patients to rely on her 10+ years of specialized clinical expertise across premier government medical institutions.

Her primary clinical focus includes intensive genetic screening and prophylactic planning for Li-Fraumeni and Lynch syndromes, targeted biological therapies for hereditary breast cancers (BRCA mutations), systemic management of multi-organ tumors in VHL and MEN, and comprehensive chemotherapy regimens for solid tumors. Her diagnostic framework incorporates advanced immunohistochemistry, molecular and genetic mutation profiling, PET-CT scan analysis, and comprehensive oncological risk stratification to formulate effective, long-term cancer survival and family-screening strategies.

At-a-Glance Profile Card

• Full Name: Dr. Sumona Das

• Primary Specialty: Medical Oncology (Systemic Cancer Treatment)

• Secondary Specialties: Hereditary Cancer Syndromes & Internal Medicine

• Designation: Consultant, Medicine Unit

• Workplace: Khulna Medical College & Hospital, Khulna

• Total Experience: 10+ Years

• Location: Khulna, Bangladesh

Qualifications & Education

• MBBS – Bachelor of Medicine and Bachelor of Surgery

• BCS (Health) – Bangladesh Civil Service (Health Cadre)

• MD (Medical Oncology) – Doctor of Medicine in Medical Oncology

• FCPS (Medicine, Part 2) – Fellow of the College of Physicians and Surgeons (Medicine, Part 2)

Designation & Workplace

• Designation: Consultant, Medicine Unit

• Workplace: Khulna Medical College & Hospital, Khulna

Diseases Treated

• Li-Fraumeni syndrome requires intensive lifelong screening for multiple primary cancers.

• Lynch syndrome (HNPCC) demands specialized colonoscopy surveillance and immunotherapy.

• Hereditary breast and ovarian cancer (BRCA) requires targeted PARP inhibitors and prophylactic surgical evaluation.

• Von Hippel-Lindau (VHL) disease needs multidisciplinary monitoring for renal cell carcinoma and hemangioblastomas.

• Multiple endocrine neoplasia (MEN) requires systemic hormonal management and tumor screening.

• Breast cancer requires systemic hormonal therapy, targeted therapy, and chemotherapy.

• Colorectal cancer requires neoadjuvant or adjuvant systemic chemotherapy and biological agents.

• Lung cancer demands advanced systemic immunotherapy and targeted molecular therapies.

• Gastric (Stomach) cancer needs systemic oncological evaluation and chemotherapy.

• Ovarian cancer demands systemic platinum-based chemotherapy and genetic profiling.

• Pancreatic cancer requires aggressive multi-agent chemotherapy regimens.

• Lymphomas (Non-Hodgkin & Hodgkin) require specialized immunochemotherapy.

• Bone and soft tissue sarcomas demand systemic neoadjuvant chemotherapy protocols.

• Internal medicine complications of cancer require rigorous metabolic and infectious disease management.

Clinical Specialties & Treatment Areas

• Hereditary & Genetic Oncology: Precision identification and management of inherited genetic mutations (like TP53, BRCA, MLH1) that cause families to develop aggressive cancers at an unusually young age.

• Medical Oncology & Systemic Therapy: Comprehensive administration of chemotherapy, immunotherapy, and targeted molecular therapies to seek out and destroy cancer cells that have spread throughout the body.

• Internal Medicine in Oncology: Expert management of the severe systemic complications of cancer and chemotherapy, including severe infections, organ failure, and metabolic imbalances.

Advanced Procedure Breakdown

Genetic Counseling & Molecular Tumor Profiling

For patients with a strong family history of cancer, Dr. Das conducts extensive genetic risk assessments. By ordering specialized molecular profiling (checking for mutations in genes like TP53, BRCA1/2, or mismatch repair genes), she determines if a cancer is hereditary. This fundamentally changes the chemotherapy plan to utilize highly targeted drugs and alerts family members to get screened early.

Targeted Systemic Chemotherapy & Immunotherapy

Unlike traditional chemotherapy that attacks all fast-growing cells, Dr. Das utilizes modern Medical Oncology protocols including targeted therapies and immunotherapy. These advanced intravenous or oral medications are selected based on the specific genetic fingerprint of the patient's tumor, effectively "unmasking" the cancer so the patient's own immune system can destroy it with fewer side effects.

High-Risk Surveillance & Prophylactic Planning

For patients diagnosed with syndromes like Li-Fraumeni or Lynch Syndrome, Dr. Das orchestrates a rigorous, lifelong surveillance protocol (frequent whole-body MRIs, early endoscopies) to catch new primary cancers at stage zero. She also collaborates with surgeons to discuss risk-reducing (prophylactic) surgeries for highly susceptible organs.

Condition-Specific Deep Dives

Li-Fraumeni Syndrome (LFS)

An exceedingly rare, inherited genetic cancer disorder most commonly caused by a mutation in the TP53 gene (the body's master tumor suppressor). Individuals with LFS have a nearly 100% lifetime risk of developing multiple, aggressive cancers, often in childhood or young adulthood. Typical cancers include sarcomas, breast cancer, brain tumors, and leukemia. It requires an extremely vigilant, specialized lifetime screening protocol.

Lynch Syndrome (HNPCC)

The most common inherited cause of colorectal cancer. Caused by mutations in DNA mismatch repair genes, it drastically increases the risk of developing colon, endometrial, ovarian, and stomach cancers at a young age. Tumors in Lynch syndrome patients frequently exhibit "microsatellite instability" (MSI-High), making them uniquely highly responsive to cutting-edge immunotherapy drugs rather than standard chemotherapy.

Von Hippel-Lindau (VHL) Disease

A rare, inherited disorder that causes tumors and cysts to grow in specific parts of the body. These tumors are highly vascular (made of newly formed blood vessels) and frequently occur in the brain, spinal cord, and retinas (hemangioblastomas). VHL heavily predisposes patients to clear cell renal cell carcinoma (kidney cancer) and pheochromocytomas, requiring meticulous systemic monitoring.

The Doctor’s Clinical Approach

Dr. Sumona Das utilizes a decade of clinical wisdom, uniquely combining her deep internal medicine foundation with her specialized medical oncology doctorate. Her philosophy emphasizes treating the whole patient—not just the tumor—by managing systemic symptoms, prioritizing genetic screening to protect the patient's wider family tree, and utilizing the latest targeted systemic therapies to maximize quality of life and survival.

Specialized Risk Factors

Emergency Callout: Immediate emergency medical evaluation is required if a chemotherapy patient develops a fever over 100.4°F (38°C) with chills (Febrile Neutropenia - a life-threatening lack of immune cells), a patient with VHL experiences sudden severe headaches, vomiting, or loss of balance (indicating a brain tumor bleed), or a patient experiences sudden, severe shortness of breath or coughing up blood (pulmonary embolism, a common cancer complication).

Certifications & Professional Memberships

• Member, Bangladesh Medical and Dental Council (BMDC)

• Consultant, BCS (Health) Cadre

• Member, Oncology Club, Bangladesh

Patient Visit Preparation Checklist

• Bring all prior biopsy reports, histopathology slides (blocks), immunohistochemistry (IHC) markers, molecular testing results, and recent PET-CT or MRI scans.

• Crucial for Genetic Cancers: Compile a detailed "Family Cancer Tree"—write down any blood relatives who had cancer, what type of cancer they had, and exactly how old they were when diagnosed.

• Maintain a complete list of current prescription medications and any previous chemotherapy discharge summaries.

• Ensure a family member accompanies the patient to take detailed notes, as medical oncology consultations involve highly complex drug regimens and side-effect management strategies.

Last Modified: October 27, 2026